Search Results (53)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| NPEPPS Is a Druggable Driver of Platinum Resistance. | Academic Article |
Why?
|
| Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. | Academic Article |
Why?
|
| Brubaker, Lindsay | Person |
Why?
|
| Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. | Academic Article |
Why?
|
| Costello, James | Person |
Why?
|
| Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. | Academic Article |
Why?
|
| Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy. | Academic Article |
Why?
|
| Drug Disposition and Nephrotoxicity | Grant |
Why?
|
| Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. | Academic Article |
Why?
|
| Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). | Academic Article |
Why?
|
| Camidge, David | Person |
Why?
|
| The Notch signaling pathway as a mediator of tumor survival. | Academic Article |
Why?
|
| Joshi, Molishree | Person |
Why?
|
| The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. | Academic Article |
Why?
|
| Afghahi, Anosheh | Person |
Why?
|